Patrizia Paterlini-Brechot,
Professor of Oncology/Molecular Biology,
University Paris Descartes
Patrizia Paterlini-Brechot, MD, PhD, is Oncologist, Hematologist and Molecular Biologist. She is a Professor of Oncology/Molecular Biology at Paris Descartes University- Necker Hospital, with a triple task of research leader, academic teacher and hospital practitioner. Prof. Paterlini-Brechot developed and patented with her team the method ISET (Isolation by SizE of Tumor/Trophoblastic cells) allowing the sensitive isolation from blood of intact circulating tumor and fetal cells without loss and without the use of antibodies, now recognized as a breakthrough in the fields of predictive oncology and non-invasive prenatal diagnosis. ISET has been proven to allow early detection of tumor invasion as a way to diagnose invasive cancers before imaging. The same ISET approach, followed by single cell molecular analyses, has been proven to provide non-invasive prenatal diagnosis of recessive disorders like cystic fibrosis and spinal muscular atrophy and is potentially valid for all types of genetic disorders.
Clinical Applications of Circulating Tumor Cells to Predictive Oncology
Wednesday, 30 October 2019 at 09:45
Add to Calendar ▼2019-10-30 09:45:002019-10-30 10:45:00Europe/LondonClinical Applications of Circulating Tumor Cells to Predictive OncologyCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Circulating Tumor Cells (CTC) and Circulating Tumor Microemboli (CTM) are Circulating Rare Cells which herald tumor invasion and are expected to provide an opportunity to improve the management of cancer patients and help to detect the most aggressive invasive cancers before other diagnostic approaches like imaging. We report on the clinical applications of CTC in predictive oncology and more specifically on the ISET® (Isolation by SizE of Tumor/Trophoblastic Cells) open system for marker-independent isolation of tumor cells from blood which allows to reliably diagnose and count CTC.
Independent published data from several international research teams have demonstrated the prognostic relevance of CTC detection by ISET® in patients with melanomas, as well as lung, colorectal, liver, pancreatic, head and neck, and ovarian cancers. Furthermore, the utility of theranostic characterization of CTC by ISET® has been demonstrated for non-small-cell lung cancers, colorectal cancers and melanomas.
Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com